Invokana Heart Attack Side Effects Reported During Clinical Trials Bring Public Concern After Lawsuit Is Filed

February 29, 2016 – – TheProductLawyers.com reports on the results of clinical trials which reviewed new-generation, type-2 diabetes drug Invokana. The results showed that the drug appeared to substantially increase the risk of heart attack for patients taking it; specifically during their first month of treatment.

In 2013, Invokana gained approval by the U.S. Food and Drug Administration (FDA), and was released for public sale as the first drug in a brand new class of several SGLT2 inhibitor drugs.

Reports from clinical trials on the drug highlighted several patients who used the medication and suddenly suffered from strokes or heart attacks; all who were 30 days or less into treatment. After the initial month, these elevated risks appeared to balance out. Researchers are unsure as to what may have caused this difference, however, it has been noted that Invokana and other diabetes drugs can raise cholesterol levels, which, in turn, can cause heart problems.

The FDA released a public statement in December of 2015 regarding Invokana’s warning label. They required manufacturer Janssen Pharmaceuticals (a division of corporate giant Johnson & Johnson) to change the product’s warning label to better reflect recent side effects they have become aware of through adverse event reports. These changes relate to another condition, however, called ketoacidosis, which takes place when the blood stream contains too much acid. In addition, the FDA addressed increased warning requirements for urinary tract infections. Heart attack and stroke risks are not mentioned on the drug’s label at this time, which is a point of contention for some. The New York Times discussed this topic in a recent article, stating, “The label of the drug includes no warnings about heart attacks or strokes…The FDA is requiring Johnson & Johnson to conduct five post-marketing studies, including a clinical trial to determine more definitively if the drug increases those risks.”

At this time, as many patients and physicians anxiously await further research, concerned experts are asking patients taking Invokana or other SGLT2 inhibitor class drugs to be hyper-aware of heart attack warning signs; especially within the first month of their treatment. These symptoms can include chest, neck, arm, shoulder, and jaw pain, dizziness, vomiting and nausea, extreme fatigue, excess sweating, and difficulty breathing.

The attorneys of Banville Law are working to assist the general public during this time by keeping them informed regarding potential health risks associated with Invokana, and lawsuits surrounding the drug. They sponsor online resource website TheProductLawyers.com, and are working to ensure that everyone who used SGLT2 inhibitors and who suffered from dangerous side effects that they attribute to the drug will be given the important opportunity to evaluate their legal rights in full. To assist these individuals, Banville Law is currently offering complimentary Invokana legal consultations.

To request more information, or to ask questions, please contact Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008411